This site is intended for healthcare professionals

Topline data announced from Phase II BLAZE 4 study of bamlanivimab, VIR 7831 (GSK 4182136) which reduced viral load by 70% in COVID 19 patients. Eli Lilly/GSK/Vir Biotech

Read time: 1 mins
Last updated:1st Apr 2021
Published:31st Mar 2021
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest